New hope for lung cancer patients when targeted drugs stop working
NCT ID NCT06868836
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called JS207, a bispecific antibody that targets PD-1 and VEGF, in combination with chemotherapy or another experimental drug (JS212) for people with advanced non-small cell lung cancer that has specific gene mutations. The participants have already tried and failed targeted therapy (TKI). The goal is to see if these combinations are safe and can shrink tumors. About 78 people will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS207 (PD-1/VEGF bispecific antibody) combined with chemotherapy (pemetrexed plus carboplatin or cisplatin) or with JS212
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung cancer whose current targeted therapy has stopped working.
- What could go wrong
- This is an early Phase 2 trial with only 78 participants, so results may not apply to everyone. The combination therapies may cause significant side effects, and there is no guarantee they will shrink tumors or extend life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provicial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- New lung cancer drug aims to match Keytruda's success
- Targeted drug shows promise for Gene-Driven lung cancers
- Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
- New drug duo aims to tackle Hard-to-Treat cancers